Fentanyl

證據等級: L5

預測適應症: 2 個

Fentanyl: From Undocumented Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

The original indication data for fentanyl is not captured in this evidence pack, and the drug is currently not marketed in Finland. The TxGNN model predicts fentanyl may be relevant to Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), with a high model score (99.46%) but zero supporting clinical trials or literature identified to date.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no licenses or original indications on file)
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis
TxGNN Prediction Score	99.46% (embedding rank 5778)
Evidence Level	L5 — model prediction only, no supporting studies
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Mechanism of action data for fentanyl is not available in this evidence pack (original_moa: [Data Gap]), and the drug's original indication(s) are also undocumented here, so the relationship between fentanyl's known pharmacology and NSIAD cannot be substantiated from the data on hand.

The model's own repurposing-rationale fields for this candidate (mechanistic_link, similarity_to_original) are marked pending — meaning no mechanistic or similarity analysis has been completed for this prediction yet. This is purely an embedding-based association from TxGNN with no corroborating clinical trials, literature, or expert-reviewed rationale at this time.

Without MOA data, original indication context, or any supporting studies, this prediction should be treated as an unvalidated model output rather than a mechanistically grounded hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Fentanyl currently has no Fimea marketing authorizations on file (total_licenses: 0), so no product/authorization table can be produced.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/Fimea package insert data is flagged as a Blocking data gap — its absence prevents completion of the initial S1 safety review for this candidate.)

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is supported only by a TxGNN model score with no clinical trials, no literature, and no completed mechanistic rationale (evidence level L5). The drug is also unmarketed in Finland, and a Blocking-severity data gap (missing TFDA/Fimea package insert) prevents even an initial safety assessment.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) — blocking gap, required before any S1 safety review
Drugbank-sourced mechanism of action (MOA) data for fentanyl
Original indication history for fentanyl to assess mechanistic similarity to NSIAD
Completion of the pending mechanistic-link and similarity-to-original analysis for this candidate
Targeted literature/clinical trial search specifically for fentanyl–NSIAD association, since current PubMed/ClinicalTrials.gov/ICTRP queries returned zero results
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.